Latest Period
Q1 2026
Security Snapshot
Alto Neuroscience, Inc. - Common Stock, par value $0.0001 per share (ANRO) Institutional Ownership
CUSIP: 02157Q109
13F Institutional Holders and Ownership History from Q1 2024 to Q1 2026
Institutions Reporting
110
Shares (Excl. Options)
26,830,701
Price
$22.48
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- ANRO on NYSE
- Shares outstanding
- 31,755,000
- Price per share
- $27.33
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 26,830,701
- Total reported value
- $602,479,913
- % of total 13F portfolios
- 0%
- Share change
- +2,359,630
- Value change
- +$54,953,807
- Number of holders
- 110
- Price from insider filings
- $27.33
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- ANRO - Alto Neuroscience, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 02157Q109.
- 110 institutions reported positions in Q1 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 96 to 110 between Q4 2025 and Q1 2026.
- Reported value moved from $435,860,904 to $602,479,913.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 110 institutions filings for Q1 2026.
Security key
02157Q109
Latest holder period
Q1 2026
13F holders
110
13D/G owners
9
CIK / CUSIP context first
Open Q1 2026 holders
ANRO full holder history
Alto Neuroscience, Inc. SEC filings
Alto Neuroscience, Inc. company facts
Alto Neuroscience, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 02157Q109:
Significant Owners of Alto Neuroscience, Inc. - Common Stock, par value $0.0001 per share (ANRO) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Commodore Capital LP | 9.9% | 0% | $77,791,742 | +$7,426,527 | 3,588,180 | +11% | Commodore Capital LP | 31 Mar 2026 |
| PERCEPTIVE ADVISORS LLC | 10% | +38% | $53,623,911 | +$20,798,926 | 3,249,934 | +63% | Perceptive Advisors LLC | 31 Dec 2025 |
| Sirenia Capital Management LP | 7.9% | $56,185,606 | 2,591,587 | Sirenia Capital Management LP | 31 Mar 2026 | |||
| Vestal Point Capital, LP | 6.5% | -19% | $44,749,146 | -$9,125,654 | 2,064,075 | -17% | Vestal Point Capital, LP | 31 Mar 2026 |
| ARMISTICE CAPITAL, LLC | 4.9% | -16% | $23,546,880 | -$981,120 | 1,536,000 | -4% | Armistice Capital, LLC | 31 Dec 2025 |
| FMR LLC | 4.7% | $2,885,445 | 1,265,546 | FMR LLC | 31 Dec 2024 | |||
| Point72 Asset Management, L.P. | 3.7% | -58% | $25,384,353 | -$35,845,929 | 1,170,865 | -59% | Steven A. Cohen | 31 Mar 2026 |
| K2 HealthVentures Equity Trust LLC | 2.4% | -53% | $13,018,418 | -$13,676,190 | 788,995 | -51% | K2 HealthVentures Equity Trust LLC | 31 Dec 2025 |
| BlackRock, Inc. | 2.1% | $1,234,213 | 561,363 | BlackRock, Inc. | 30 Jun 2025 |
As of 31 Mar 2026, 110 institutional investors reported holding 26,830,701 shares of Alto Neuroscience, Inc. - Common Stock, par value $0.0001 per share (ANRO). This represents 84% of the company’s total 31,755,000 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Alto Neuroscience, Inc. - Common Stock, par value $0.0001 per share (ANRO) together control 74% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Alpha Wave Global, LP | 12% | 3,707,757 | 0% | 11% | $83,350,377 |
| Commodore Capital LP | 8.6% | 2,723,196 | +49% | 3.5% | $61,217,446 |
| Vestal Point Capital, LP | 6.5% | 2,064,075 | -17% | 1.3% | $46,400,406 |
| PERCEPTIVE ADVISORS LLC | 6.3% | 2,009,893 | +13% | 0.89% | $45,182,395 |
| Spruce Street Capital LP | 4.2% | 1,325,210 | +495% | 7% | $29,116,321 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.8% | 1,207,025 | 0% | 0% | $27,133,922 |
| FRANKLIN RESOURCES INC | 3.5% | 1,101,874 | -1.6% | 0.01% | $24,770,128 |
| Vivo Capital, LLC | 3.3% | 1,035,551 | 0% | 1.9% | $23,279,186 |
| ARMISTICE CAPITAL, LLC | 2.9% | 912,000 | -41% | 0.68% | $20,501,760 |
| MILLENNIUM MANAGEMENT LLC | 2.6% | 821,982 | +30% | 0.01% | $18,478,155 |
| 72 Investment Holdings, LLC | 2.1% | 667,778 | 0% | 30% | $15,011,649 |
| BlackRock, Inc. | 2.1% | 666,188 | +9.6% | 0% | $14,975,907 |
| Ikarian Capital, LLC | 1.6% | 515,000 | 0% | 1.7% | $11,577,200 |
| Point72 Asset Management, L.P. | 1.6% | 503,087 | -69% | 0.02% | $11,309,396 |
| Affinity Asset Advisors, LLC | 1.6% | 500,000 | 0.66% | $11,240,000 | |
| Integral Health Asset Management, LLC | 1.6% | 500,000 | +33% | 0.59% | $11,240,000 |
| Venrock Adviser, LLC | 1.6% | 500,000 | 0.42% | $11,240,000 | |
| Driehaus Capital Management LLC | 1.5% | 486,726 | +45% | 0.08% | $10,942,410 |
| NORTHERN TRUST CORP | 1.5% | 473,403 | -0.2% | 0% | $10,642,099 |
| JENNISON ASSOCIATES LLC | 1.2% | 386,426 | 0.01% | $8,686,856 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.2% | 385,000 | 0.01% | $8,654,800 | |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.2% | 371,208 | +1128% | 0% | $8,346,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.92% | 292,899 | +1.9% | 0% | $6,587,938 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.75% | 238,498 | +102% | 0.01% | $5,361,435 |
| ALKEON CAPITAL MANAGEMENT LLC | 0.72% | 227,101 | -52% | 0.02% | $5,105,230 |
Institutional Holders of Alto Neuroscience, Inc. - Common Stock, par value $0.0001 per share (ANRO) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 26,830,701 | $602,479,913 | +$54,953,807 | $22.48 | 110 |
| 2025 Q4 | 24,487,002 | $435,860,904 | +$135,656,607 | $17.80 | 96 |
| 2025 Q3 | 16,755,091 | $67,358,617 | -$1,672,076 | $4.02 | 74 |
| 2025 Q2 | 17,296,212 | $38,050,471 | -$7,942,231 | $2.20 | 78 |
| 2025 Q1 | 20,845,367 | $45,026,701 | -$4,167,716 | $2.16 | 83 |
| 2024 Q4 | 22,530,140 | $95,292,066 | -$45,543,045 | $4.23 | 77 |
| 2024 Q3 | 22,939,574 | $265,498,730 | +$37,026,413 | $11.44 | 75 |
| 2024 Q2 | 18,600,674 | $198,841,035 | +$25,849,471 | $10.69 | 58 |
| 2024 Q1 | 15,971,812 | $245,167,778 | +$245,167,778 | $15.35 | 52 |